RGEN - What's Going On With Life Science-Focused Repligen Stock Today? | Benzinga
Repligen Corporation (NASDAQ:RGEN) reported fourth-quarter 2023 adjusted EPS of $0.33, in line with the consensus estimate.
The life science company reported sales of $155.74 million, down from $186.8 million a year ago, beating the consensus of $155.39 million.
Base revenue (non-GAAP) for the quarter was $142.1 million, compared to $163.0 million a year ago.
Tony Hunt, CEO, said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter.”
The company says ...